Loading...
Loading...
IMGN| Name | Value |
|---|---|
| Revenues | 113.4M |
| Cost of Revenue | 2.2M |
| Gross Profit | 111.3M |
| Operating Expense | 85.3M |
| Operating I/L | 26.0M |
| Other Income/Expense | -0.2M |
| Interest Income | 4.8M |
| Pretax | 29.6M |
| Income Tax Expense | -1.2M |
| Net Income/Loss | 30.7M |
ImmunoGen, Inc. is a clinical-stage biotechnology company specializing in the development of antibody-drug conjugate (ADC) therapies for cancer treatment. The company's product candidates include mirvetuximab soravtansine, targeting folate-receptor alpha (FRa) for platinum-resistant ovarian cancer, and Pivekimab sunirine, a CD123-targeting ADC for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen also has preclinical programs such as IMGC936 and IMGN151. The company generates revenue through collaborations with leading pharmaceutical companies like Roche, Amgen, Bayer, Eli Lilly, and Novartis, as well as through co-development partnerships with other biotech firms like MacroGenics and CytomX Therapeutics.
